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Introduction {#sec005}
============

Morbidity and mortality of HIV-infected people treated with combination antiretroviral therapy (cART) are now dominated by non AIDS-defining events (NADE) \[[@pone.0161594.ref001]--[@pone.0161594.ref005]\]. As in general population, NADE could be promoted by multiple factors, including comorbidities such as chronic hepatitis, arterial hypertension and diabetes, and high-risk behaviours such as smoking and alcohol consumption \[[@pone.0161594.ref006]--[@pone.0161594.ref007]\]. There is however a persistent higher incidence of morbid events in HIV-infected patients compared to the general population, which might be driven by specific factors among which immune activation linked to accelerated aging seem to be prominent \[[@pone.0161594.ref008]--[@pone.0161594.ref010]\].

While normalisation of CD4+ cells count above 500/mm^3^ is frequent under cART, normalisation of CD4/CD8 ratio above 1 is much slower, due mostly to persistence of elevated CD8 cell counts \[[@pone.0161594.ref011]\]. This persistently low CD4/CD8 ratio has been demonstrated to reflect persistent innate and adaptive immune activation in HIV-infected patients \[[@pone.0161594.ref012]\]. Moreover, in the general population, a low CD4/CD8 ratio is associated with risk of death in the elderly \[[@pone.0161594.ref013]\] and may thus be a marker of early immunosenescence in HIV-infected patients. We thus hypothesized that CD4/CD8 ratio, an easily available marker of persistent immune activation, might be a predictor of morbidity in HIV-infected patients on cART. We specifically searched to determine whether the CD4/CD8 ratio brought more information than usual immunological and virological markers in predicting the occurrence of NADE in a cohort of HIV-infected patients with a long-term follow-up on cART.

Methods {#sec006}
=======

Patients and variables {#sec007}
----------------------

The ANRS CO8 (Aproco/Copilote) cohort study was conducted in 47 clinical centres in France from 1997 to 2009 \[[@pone.0161594.ref014]\]. In total, 1281 patients were enrolled between May 1997 and June1999 at the first initiation of a protease inhibitor-containing antiretroviral therapy and followed in the cohort until December 2009. After the inclusion visit, patients were followed at 1 and 4 months after initiation of treatment, and then every 4 months. During follow-up visits, CD4+ and CD8+ cells counts, and plasma HIV RNA were updated. Severe clinical events were recorded prospectively, monitored by clinical research assistants and validated by an event validation committee \[[@pone.0161594.ref001]\]. All cancers were histologically proven. An event was considered severe when life threatening or leading to hospitalization or death. Non AIDS-defining severe events were those that did not fulfil the criteria for AIDS according to the 1993 CDC classification and were not obviously related to antiretroviral drugs \[[@pone.0161594.ref001]\]. HCV infection was defined by the presence of anti-HCV antibodies and HBV infection by the presence of HBs antigen. Socioeconomic and behavioural characteristics, including alcohol and tobacco consumptions, were collected using a self-administered questionnaire at baseline. All patients included in the APROCO/COPILOTE cohort provided written informed consent and the protocol was approved by the "Comité de Protection des Personnes se prêtant à la Recherche Biomédicale" of the Cochin Hospital (Paris).

Statistical analysis {#sec008}
--------------------

For the description of NADE and the analysis of potential determinants of the occurrence of the first NADE during long-term cART, we selected only NADE that occurred after the initial response to cART, i.e. after 4 months of follow-up (M4). Therefore, patients who died or were lost to follow-up before M4 were excluded from analyses.

Potential determinants of the occurrence of the first NADE after M4 were studied using Cox proportional hazards regression models. Data were censored at last follow-up in the cohort or death. Plasma HIV RNA, CD4+ cell count (CD4) and CD4/CD8 ratio recorded during follow-up after M4 as well as a composite immune restoration variable built in three categories (CD4\< 500/mm^3^, CD4 \> 500/mm^3^ and CD4/CD8 ratio ≤ 1, CD4 \> 500/mm^3^ and CD4/CD8 ratio \> 1), were treated as time-dependent variables. We first studied the association between time-dependent CD4+ cells count, CD4/CD8 ratio and the occurrence of NADE in bivariate analyses. The cut-off values for transformation of these two continuous variables into categorical variables were those having the maximal likelihood in the bivariate analyses using the Akaike information criterion (AIC). Then we constructed a multivariable model of predictors of first non-AIDS defining event, including baseline characteristics and time-dependent plasma HIV RNA level. Variables associated with a p-value of 0.25 in bivariable analysis were included in the initial multivariable model and a backward selection procedure retaining only significant variables (p \< 0.05) was then used to yield a final multivariable model.

Finally, we used the AIC (the lower value being associated with maximal likelihood and thus with best prediction of outcome) to compare the four following Cox models adjusted on baseline variables and time-dependent plasma HIV RNA: (i) model with CD4, (ii) model with CD4/CD8 ratio, (iii) model with both CD4 and CD4/CD8 ratio, (iv) model with the composite immune restoration variable.

The same approach was then used to analyse the first non AIDS-defining bacterial infection, the first cardiovascular event, and the first non AIDS-defining cancer respectively. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Inc, Cary, NC, USA).

Results {#sec009}
=======

Of the 1281 patients included in the cohort, 1227 (96%) patients having at least four months of follow-up were selected for the present analysis. The median duration of follow-up was 9.2 years, (interquartile range (IQR): 4.2--11.4). At baseline the median age was 36 years (IQR 32--43), men accounted for 77% of the sample, the main presumed mode of transmission was sex between men (40.1%) and 44.7% of patients were antiretroviral naïve. Median baseline CD4+ cells count was 278/ mm^3^ (IQR 129--422), median CD4/CD8 ratio was 0.3 (IQR 0.2--0.5) and 98.1% of patients had a CD4/CD8 ratio less than 1. Median plasma HIV RNA was 4.5 log~10~ copies/ml (IQR 3.7--5.2).

The majority of patients had immunological and virological response to cART. The proportion of patients with plasma HIV RNA \< 500 copies/mL was 60% at 12 months, 87% at 9 years and 93% at 12 years. Median CD4+ cell count was 410/ mm^3^ at 12 months, 530/mm^3^ at 9 years and 585/mm^3^ at 12 years. The proportion of patients with CD4+ cells count \> 500/mm^3^ was 60% at 9 years and 74% at 12 years. Median CD4/CD8 ratio increased during follow-up to reach 0.6 (IQR: 0.3--0.9) at 9 years and 0.8 (IQR: 0.5--1.1) at 12 years of follow-up, the proportion of patients having a CD4/CD8 ratio \> 1 reaching 20% at 9 years and 30% at 12 years.

During follow-up, 536 of 1227 patients 43.7%) in the study had at least one NADE after M4, totalising 1152 NADE throughout follow-up ([Table 1](#pone.0161594.t001){ref-type="table"}). Incidence of first NADE was 7.4/100 persons-years of follow-up. The most common were bacterial infections (21%), cardiovascular events (14%) and cancers (10%). In multivariable analysis without any measure of immune restoration, occurrence of first NADE was associated with older age, CDC stage C, HCV and HBV infection at baseline and time-dependent plasma HIV RNA level (hazard ratio = 0.70 for HIV RNA \< 500 copies/mL vs \> 500 copies/mL (95% confidence interval: 0.58--0.8). Associations with gender, transmission risk group, alcohol or tobacco use at baseline were not significant ([Table 2](#pone.0161594.t002){ref-type="table"}).

10.1371/journal.pone.0161594.t001

###### Description of the 1152 non-AIDS defining events observed in 1227 patients who had at least four months in the follow-up.

APPROCO/ COPILOTE (ANRS CO8) cohort study 1997--2009.

![](pone.0161594.t001){#pone.0161594.t001g}

  Non-AIDS defining events                         n (%)
  ------------------------------------------------ ----------------
  **Bacterial infections**                         **241 (20.9)**
   Airway bacterial infections                     122 (10.5)
    Upper airway bacterial infections              7 (0.6)
    Lower airway bacterial infections              115 (10.0)
   Intra-abdominal infections                      43 (3.7)
   Skin and soft tissue infections                 17 (1.5)
   Anal and perianal infections                    8 (0.7)
   Bone and joint infections                       7 (0.6)
   Bacteremia                                      19 (1.7)
   Urinary tract infections                        15 (1.3)
   Other bacterial infections                      10 (0.9)
  **Cardiovascular events**                        **160 (13.9)**
   **Ischemic events**                             **103(8.9)**
    Coronary events                                59 (5.1)
    Arterial events                                28 (2.4)
    Strokes                                        12 (1.0)
    Other ischemic events                          4 (0.4)
   Non-ischemic events                             26 (2.3)
   Vascular events                                 36 (2.7)
  **Cancers**                                      **116 (10.1)**
   Solid cancers                                   103 (8.9)
    Digestive cancers                              40 (3.5)
     Oesophagus                                    2 (0.2)
     Stomach                                       5 (0.4)
     Hepatocellular carcinoma                      12 (1.0)
     Pancreas                                      5 (0.4)
     Colon and rectum                              6 (0.5)
     Anus                                          6 (0.5)
     Other digestive cancer                        4 (0.3)
    Larynx and pharynx                             14 (1.2)
    Bladder and urinary tract                      10 (0.9)
    Lung                                           12 (1.0)
    Skin                                           11 (1.0)
    Other solid cancers                            16 (1.4)
   Hodgkin lymphoma                                13 (1.1)
  **Digestives events**                            **97 (8.4)**
   Cirrhosis                                       24 (2.1)
   Pancreatitis                                    17 (1.5)
   Others                                          56 (4.9)
  **Psychiatric events**                           **73 (6.3)**
   Depression with or without suicide attempt      55 (4.8)
   Other psychiatric disorders                     18 (1.6)
  **Neurological events**                          **56 (4.9)**
   Neurological events of central origin           34 (3.0)
   Peripheral neuropathy                           22 (1.9)
  **Kidney and urinary tract events**              **68 (5.9)**
  **Viral infections**                             **34 (3.0)**
   Varicella zoster infections                     15 (1.3)
   Other viral infections                          19 (1.7)
  Surgical diseases                                55 (4.8)
  Skin diseases                                    11 (1.0)
  Endocrine diseases                               10 (0.9)
  Gynecological diseases                           10 (0.9)
  Hematological diseases                           18 (1.6)
  Events in relation with drug addiction           16 (1.4)
  Ophtalmological diseases                         7 (0.6)
  Lung events                                      32 (2.8)
  Rheumatological events                           33 (2.9)
  Trauma                                           40 (3.5)
  General symptoms                                 25 (2.1)
  Hypersensitivity reactions not related to cART   18 (1.6)
  Deaths of unknown origin                         10 (0.9)
  Other events (scabies, malaria...)               22 (1.9)

10.1371/journal.pone.0161594.t002

###### Factors associated with the occurrence of the first non-AIDS events.

Final multivariate model without any measure of immune restoration. APPROCO/ COPILOTE (ANRS CO8) cohort study 1997--2009.
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  Factor studied                              Non-AIDS events n (%)   Crude HR   p          Adjusted HR   95%CI        p
  ------------------------------------------- ----------------------- ---------- ---------- ------------- ------------ ---------
  Age at baseline (years)                                                        0.02                                  \<0.001
   \<30                                       71 (38.0)               1                     1                          
   \[30--40\]                                 247 (40.4)              0.95                  0.85          0.64--1.12   
   \[40--50\]                                 136 (48.6)              1.13                  1.10          0.82--1.48   
   \[50--60\]                                 53 (51.5)               1.25                  1.34          0.93--1.93   
   ≥ 60                                       29 (63.0)               1.75                  1.93          1.25--3.01   
  Gender                                                                         0.63                                  
   Male                                       415 (43.8)              1                                                
   Female                                     121 (43.2)              1.05                                             
  Presumed route of HIV transmission                                             \< 0.001                              
   Sex between men                            189 (38.4)              1                                                
   Sex between men and women                  175 (42.9)              1.19                                             
   Intravenous drug use                       105 (53.6)              1.77                                             
   Haemophilia                                9 (69.2)                2.37                                             
   Others/unknown                             40 (42.1)               1.19                                             
  CDC stage C at baseline                                                        0.03                                  0.025
   No                                         411 (42.0)              1                     1                          
   Yes                                        125 (50.4)              1.24                  1.26          1.02--1.55   
  Tobacco smoking at baseline                                                    0.02                                  
   Yes or unknown                             357 (45.0)              1                                                
   No                                         179 (41.3)              0.81                                             
  Alcohol consumption at baseline                                                0.04                                  
   Yes or unknown                             437 (42.9)              1                                                
   No                                         99 (47.6)               1.25                                             
  HBV infection                                                                  0.04                                  0.021
   No                                         504 (43.2)              1                     1                          
   Yes                                        32 (54.2)               1.46                  1.49          1.04--2.14   
  HCV infection                                                                  \< 0.001                              \<0.001
   No                                         381 (40.1)              1                     1                          
   Yes                                        155 (56.2)              1.64                  1.76          1.45--2.15   
  Time-dependent plasma HIV RNA (copies/mL)                                      0.001                                 \<0.001
   ≥ 500                                      \-                      1                     1                          
   \< 500                                                             0.73                  0.70          0.58--0.85   

Abbreviations: HR: hazard ratio; CI: confidence interval.

When comparing adjusted models including four different measures of immune restoration during follow-up, the model associated with the maximum likelihood was the model containing only time-dependent CD4+ cells count and the higher risk of morbidity was associated with a last CD4+ cells count \< 100/mm^3^, while the difference between higher strata of CD4+ cells count was minimal ([Table 3](#pone.0161594.t003){ref-type="table"}).

10.1371/journal.pone.0161594.t003

###### Comparison of four measures of immune restoration in prediction of occurrence of first non AIDS-defining severe events.

ANRS CO8 (APROCO/COPILOTE) 1997--2009.
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  -------------------------------- ---------------------------------------------------------- ------------ ---------
  **Model 1 *AIC = 6772*.*54***                                                                            
  **Time-dependent variable**      **Adjusted**[\*](#t003fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  CD4+ cell count (/mm^3^)                                                                                 
   \<100                           1                                                                       
   100--200                        0.39                                                       0.25--0.60   \<0.001
   200--500                        0.43                                                       0.30--0.61   \<0.001
   ≥ 500                           0.31                                                       0.21--0.46   \<0.001
  **Model 2 *AIC = 6796*.*47***                                                                            
  **Time-dependent variable**      **Adjusted**[\*](#t003fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  CD4/CD8 ratio                                                                                            
   *\<0*.*5*                       1                                                                       
   *0*.*5--1*                      0.86                                                       0.71--1.05   0.16
   *≥ 1*                           0.71                                                       0.53--0.96   0.03
  **Model 3 *AIC = 6787*.*38***                                                                            
  **Time-dependent variable**      **Adjusted**[\*](#t003fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  Immune restoration variable                                                                              
   CD4 ≥ 500/mm^3^, CD4/CD8 ≤ 1    1                                                                       
   CD4 ≥ 500/mm^3^, CD4/CD8 \> 1   0.88                                                       0.62--1.23   0.46
   CD4 \< 500/mm^3^                1.39                                                       1.13--1.70   0.001
  **Model 4 *AIC = 6772*.*36***                                                                            
  **Time-dependent variable**      **Adjusted**[\*](#t003fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  CD4+ cell count (/mm^3^)                                                                                 
   \<100                           1                                                                       
   100--200                        0.39                                                       0.25--0.60   \<0.001
   200--500                        0.43                                                       0.30--0.61   \<0.001
   ≥ 500                           0.31                                                       0.21--0.46   \<0.001
  CD4/CD8 ratio                                                                                            
   \<0.5                           1                                                                       
   0.5--1                          1.02                                                       0.82--1.26   0.85
   ≥ 1                             0.88                                                       0.64--1.22   0.46
  -------------------------------- ---------------------------------------------------------- ------------ ---------

Abbreviations: AIC: Akaike Information Criterion. HR: hazard ratio; CI: confidence interval.

\* Adjusted on age, stage AIDS, plasma HIV RNA level, HCV and HBV infections.

We performed the same analyses for the first non AIDS-defining severe bacterial infection, the first cardiovascular severe event, and the first non AIDS-cancer respectively. The CD4/CD8 ratio did not add supplementary prognostic information when added to the CD4+ cell count (data not shown for bacterial infections and cardiovascular events), except for the prediction of the first non-AIDS cancer for which both CD4+ cell count \< 100/mm^3^ and CD4/CD8 \< 0.5 were independently associated with a higher risk of event and the model containing only the CD4/CD8 ratio was associated with the higher likelihood with an HR of 2.13 for CD4/CD8 \< 0.5 vs ≥ 0.5 (95% CI = 0.31--0.90) ([Table 4](#pone.0161594.t004){ref-type="table"}).

10.1371/journal.pone.0161594.t004

###### Comparison of four measures of immune restoration in prediction of occurrence of first non AIDS-defining cancer.

ANRS CO8 (APROCO/COPILOTE) 1997--2009.
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  -------------------------------- ---------------------------------------------------------- ------------ -------
  **Model 1 *AIC = 936*.*79***                                                                             
  **Time-dependent variable**      **Adjusted**[\*](#t004fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  CD4+ cell count (/mm^3^)                                                                                 
   \<100                           1                                                                       
   100--200                        0.22                                                       0.05--0.92   0.04
   200--500                        0.35                                                       0.13--0.92   0.03
   ≥ 500                           0.22                                                       0.08--0.59   0.002
  **Model 2 *AIC = 932*.*16***                                                                             
  **Time-dependent variable**      **Adjusted**[\*](#t004fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  CD4/CD8 ratio                                                                                            
   *\<0*.*5*                       2.13                                                       1.32--3.45   0.002
   *≥0*.*5*                        1                                                                       
  **Model 3 *AIC = 938*.*41***                                                                             
  **Time-dependent variable**      **Adjusted**[\*](#t004fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  Immune restoration variable                                                                              
   CD4 ≥ 500/mm^3^, CD4/CD8 ≤ 1    1                                                                       
   CD4 ≥ 500/mm^3^, CD4/CD8 \> 1   0.64                                                       0.62--1.23   0.34
   CD4 \< 500/mm^3^                1.47                                                       0.87--2.47   0.14
  **Model 4 *AIC = 933*.*40***                                                                             
  **Time-dependent variable**      **Adjusted**[\*](#t004fn002){ref-type="table-fn"} **HR**   **95% CI**   **p**
  CD4+ cell count (/mm^3^)                                                                                 
   \<100                           1                                                                       
   100--200                        0.23                                                       0.05--0.96   0.04
   200--500                        0.43                                                       0.16--1.14   0.09
   ≥ 500                           0.35                                                       0.12--1.00   0.05
  CD4/CD8 ratio                                                                                            
   \<0.5                           1                                                                       
   ≥0.5                            0.53                                                       0.31--0.90   0.02
  -------------------------------- ---------------------------------------------------------- ------------ -------

Abbreviations: AIC: Akaike Information Criterion. HR: hazard ratio; CI: confidence interval.

\* Adjusted on age and HCV infection.

Discussion {#sec010}
==========

In the Aproco/Copilote cohort, the CD4/CD8 ratio increased progressively over time and continued to increase until 12 years of follow-up on cART, but remained below 1 for the majority of patients. The study confirmed the high incidence of NADE in this cohort and showed that these events were associated with persistence of profound immunodeficiency, i.e. very low CD4+ cell count under treatment. This association was however mainly observed in the minority of patients who had CD4 cells count remaining below 100/ mm^3^. The CD4/CD8 ratio did not add predictive information on morbidity to the CD4+ cells count, except for non-AIDS cancers for which a ratio \< 0.5 constituted the main immunological predictor of these events with a twice higher risk of non AIDS cancer in patients with a CD4/CD8 ratio \< 0.5.

One of the strengths of our study is the extended follow-up duration, giving both chance to observe a high number of events and time to observe immune restoration. To our knowledge, this study is the first to analyse morbidity on cART with such an extended follow-up duration. In addition, by recruiting patients in 47 medical centres in France with a standardised data collection carried out by qualified personnel, this study gave us a good representation of the population of patients who started cART in France in the late 1990s. Moreover, all severe events in the cohort were monitored, which gave us completeness in the collection of events. These events were validated by an endpoint review committee constituted by experienced clinicians (see events validation committee in appendix), which reinforces the validity of the diagnoses. These strengths probably compensate, at least in part, for the relatively small number of patients. Among the limitations of the study, the most important is probably also the recruitment of patients in the late 1990's, during the early days of cART, where regimens were still suboptimal because of late initiation, previous exposure to nucleoside analogues and insufficient potency of the initially prescribed third agent, a first-generation unboosted protease inhibitor. The proportion of patients reaching a high CD4/CD8 ratio may be higher for patients who initiate cART nowadays with more potent combinations, although this might not be the case for late-presenters. However, because the relationship between a biological marker and morbidity is unlikely to evolve greatly over time, we believe that our main findings still apply to people currently initiating cART. Moreover, thanks to the high potency of cART, patients who initiated antiretrovirals in the 1990s still represent an important proportion of people living with HIV in industrialized countries.

In our study, despite CD4 reconstitution with cART, the CD4/CD8 ratio increased but remained below 1 for most patients. Other authors have also evidenced such a slow increase with time. Tinago et al. in Ireland, showed that only 26% of patients treated with cART had a CD4/CD8 ratio greater than 1 after 14 years of follow-up \[[@pone.0161594.ref015]\]. Leung et al. in Canada, studied the predictors of normalization of CD4/CD8 ratio, defined as a ratio greater than 1.2, in over 4,000 HIV-infected patients initiating cART between 2000 and 2010 with a median follow-up duration of less than 3 years. In this cohort, only 7.2% of patients had a CD4/CD8 ratio ≥ 1.2 at the end of follow-up \[[@pone.0161594.ref016]\]. HIV RNA suppression, high baseline CD4+ cell counts and low baseline CD8+ cell count were the main predictors of normalisation of the CD4/CD8 ratio. In the Italian cohort ICONA, the proportion of normalisation of CD4/CD8 ratio above 1 was 29.4% at 5 years of follow-up and an additional factor found associated with higher ratio was the lack of co-infection with cytomegalovirus (CMV) \[[@pone.0161594.ref017]\], a data that was not available in our cohort. Co-infection with CMV was also a determinant of a lower probability to reach a CD4/CD8 ratio above 1 in a transversal study conducted in Paris \[[@pone.0161594.ref018]\]. The mechanisms underlying the slow recovery of CD4/CD8 ratio despite the effectiveness of cART remain poorly understood. A persistent deficiency in naive CD8+ T cells \[[@pone.0161594.ref015]\] and/or a persistent activation of CD8+ lymphocytes linked to persistent viral production or immune activation \[[@pone.0161594.ref012]\] have been invoked, as well as a dysfunction of CD4+ regulatory T lymphocytes \[[@pone.0161594.ref019]\].

Low CD4/CD8 ratio does not seem to increase the risk of AIDS or death nowadays \[[@pone.0161594.ref016]\], which was not true in the earlier cART era \[[@pone.0161594.ref020]\]. We found that the CD4/CD8 did not provide additional information to the CD4+ cell count in predicting the now much more frequent non-AIDS-defining events, except for cancers. Our results are in discordance with those of three previous studies. Mussini et al. in a study performed in the Italian cohort ICONA found a higher risk of non-AIDS defining events in patients with a CD4/CD8 ratio \< 0.3, independently of the CD4+ cell count \[[@pone.0161594.ref017]\]. In this study, the most frequent event was acute kidney injury, which is quite unusual. Serrano-Villar et al showed in the Madrid cohort that the CD4/CD8 ratio was significantly lower in patients suffering from non AIDS events compared to the other patients of the cohort, independently of CD4+ cells count and other prognostic factors, and this finding was consistent for all types of events including cardiovascular ones and end-stage kidney disease \[[@pone.0161594.ref021]\]. Of note, the number of events was low and the study used a case-control design, which is associated with a lower level of evidence than prospective studies. In the Aquitaine cohort, a study focusing on severe bacterial infections showed that these events were more frequent in patients with a CD4/CD8 ration\< 0.8 \[[@pone.0161594.ref022]\]. A study performed in the US in patients enrolled between 1998 and 2012 showed results more in accordance with ours, i.e. a lack of association between low CD4/CD8 ratio and well-characterized NADE when adjusting for CD4+ cell counts \[[@pone.0161594.ref023]\]. Of note, in this latter study, when assessing NADE by category, low CD4/CD8 ratio was associated with a higher risk of coronary artery disease but not of cancer.

According to our findings, the CD4/CD8 ratio may not provide much additional information to the CD4+ cell count in predicting the occurrence of all types of non-AIDS defining events. Even if immune activation is probably a major driver of morbidity, this result is probably explained by the fact that, for most morbid events occurring in patients infected with HIV, like cardiovascular disease or neuropsychological conditions, the main drivers are probably aging, comorbidities and/or behaviour. Yet, non-AIDS-defining events are an extremely heterogeneous group that often have little in common on a pathophysiological point of view. Therefore, to study them as if they were a single event type, as is most usually done, appears questionable. In particular, the type of immune activation that favours each specific comorbidity may be at least in part specific. CD4/CD8 ratio is an indicator of CD4+ T cell lymphopenia and of CD8+ T cell activation and some comorbidities may depend on none of these factors. Our analysis showed actually that the effect of immune restoration and/or CD8+ T cell activation was quite different according to the type of event with an independent role of the CD4/CD8 ratio evidenced only on the risk of cancer. Independently of CD4+ cells count, the risk of cancer was indeed twice higher in the subset of patients who had a CD4/CD8 ratio below 0.5. A previous study, performed in patients on cART or not in the Swiss HIV cohort, is in accordance with our findings, by showing a higher risk of Hodgkin lymphoma in patients having a very low CD4/CD8 ratio \< 0.25, 1 to 2 years before diagnosis of malignancy \[[@pone.0161594.ref024]\]. Due to the low number of events, we were not able to search for an effect of the CD4/CD8 ratio on specific types of cancers.

The CD4/CD8 ratio is easily available in clinical practice but rarely used in measuring immunological response to cART. A low CD4/CD8 ratio reflects indeed quite different situations, including low CD4+ cell count and/or persistent CD8+ T cell immune proliferation, which may preclude its clinical utility. However, our study suggests that monitoring CD4/CD8 ratio in patients receiving ART may be useful to identify a subset of patients at much higher risk of non AIDS-defining cancer who may thus require a more intensive strategy of prevention or screening.
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